153 related articles for article (PubMed ID: 27419077)
1. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors.
Deshpande N; V S; V V RK; H V V M; M S; Banerjee R; Tandan M; D NR
Meta Gene; 2016 Sep; 9():159-64. PubMed ID: 27419077
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 polymorphism and proton pump inhibitors.
Klotz U; Schwab M; Treiber G
Basic Clin Pharmacol Toxicol; 2004 Jul; 95(1):2-8. PubMed ID: 15245569
[TBL] [Abstract][Full Text] [Related]
4. Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.
Karaca RO; Kalkisim S; Altinbas A; Kilincalp S; Yuksel I; Goktas MT; Yasar U; Bozkurt A; Babaoglu MO
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):199-206. PubMed ID: 27611887
[TBL] [Abstract][Full Text] [Related]
5. The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors.
Sychev DA; Denisenko NP; Sizova ZM; Grachev AV; Velikolug KA
Pharmgenomics Pers Med; 2015; 8():111-4. PubMed ID: 26109874
[TBL] [Abstract][Full Text] [Related]
6. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
7. [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole.
Furuta T; Kodaira C; Nishino M; Yamade M; Sugimoto M; Ikuma M; Hishida A; Watanabe H; Umemura K
Aliment Pharmacol Ther; 2009 Aug; 30(3):294-300. PubMed ID: 19459830
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
9. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
[TBL] [Abstract][Full Text] [Related]
10. Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?
Ormeci A; Emrence Z; Baran B; Soyer OM; Gokturk S; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1795-7. PubMed ID: 27212172
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.
Kita T; Tanigawara Y; Aoyama N; Hohda T; Saijoh Y; Komada F; Sakaeda T; Okumura K; Sakai T; Kasuga M
Pharm Res; 2001 May; 18(5):615-21. PubMed ID: 11465416
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy.
Ram M R; Teh X; Rajakumar T; Goh KL; Leow AHR; Poh BH; Mariappan V; Shankar EM; Loke MF; Vadivelu J
J Antimicrob Chemother; 2019 Jan; 74(1):11-16. PubMed ID: 30403784
[TBL] [Abstract][Full Text] [Related]
13. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Egan LJ; Myhre GM; Mays DC; Dierkhising RA; Kammer PP; Murray JA
Aliment Pharmacol Ther; 2003 Jun; 17(12):1521-8. PubMed ID: 12823155
[TBL] [Abstract][Full Text] [Related]
15. The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
Modak AS; Klyarytska I; Kriviy V; Tsapyak T; Rabotyagova Y
J Breath Res; 2016 Dec; 10(4):046017. PubMed ID: 27991432
[TBL] [Abstract][Full Text] [Related]
16. The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury.
Nuki Y; Umeno J; Washio E; Maehata Y; Hirano A; Miyazaki M; Kobayashi H; Kitazono T; Matsumoto T; Esaki M
Aliment Pharmacol Ther; 2017 Aug; 46(3):331-336. PubMed ID: 28481007
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
18. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
19.
Miftahussurur M; Doohan D; Syam AF; Nusi IA; Subsomwong P; Waskito LA; Maulahela H; Akil F; Uwan WB; Siregar G; Fauzia KA; Rezkitha YAA; Rahman A; Wibawa IDN; Saudale AMJ; Richardo M; Sugihartono T; Chomariyati A; Bramantoro T; Uchida T; Yamaoka Y
Biology (Basel); 2021 Apr; 10(4):. PubMed ID: 33917299
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
